These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Cancer chemotherapy with lipid-based nanocarriers. Liu D; Zhang N Crit Rev Ther Drug Carrier Syst; 2010; 27(5):371-417. PubMed ID: 21083528 [TBL] [Abstract][Full Text] [Related]
23. Radiosensitization of TPGS-emulsified docetaxel-loaded poly(lactic-co-glycolic acid) nanoparticles in CNE-1 and A549 cells. Shi W; Yuan Y; Chu M; Zhao S; Song Q; Mu X; Xu S; Zhang Z; Yang K J Biomater Appl; 2016 Mar; 30(8):1127-41. PubMed ID: 26608458 [TBL] [Abstract][Full Text] [Related]
24. Targeting of nanoparticles in cancer: drug delivery and diagnostics. Talekar M; Kendall J; Denny W; Garg S Anticancer Drugs; 2011 Nov; 22(10):949-62. PubMed ID: 21970851 [TBL] [Abstract][Full Text] [Related]
25. Folate-targeted docetaxel-lipid-based-nanosuspensions for active-targeted cancer therapy. Wang L; Li M; Zhang N Int J Nanomedicine; 2012; 7():3281-94. PubMed ID: 22802688 [TBL] [Abstract][Full Text] [Related]
26. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel. Cho HJ; Yoon HY; Koo H; Ko SH; Shim JS; Lee JH; Kim K; Kwon IC; Kim DD Biomaterials; 2011 Oct; 32(29):7181-90. PubMed ID: 21733572 [TBL] [Abstract][Full Text] [Related]
27. Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition. Jiang Y; Yang N; Zhang H; Sun B; Hou C; Ji C; Zheng J; Liu Y; Zuo P J Control Release; 2016 Jan; 221():26-36. PubMed ID: 26643616 [TBL] [Abstract][Full Text] [Related]
28. Simultaneous Targeting of Differentiated Breast Cancer Cells and Breast Cancer Stem Cells by Combination of Docetaxel- and Sulforaphane-Loaded Self-Assembled Poly(D, L-lactide-co-glycolide)/Hyaluronic Acid Block Copolymer-Based Nanoparticles. Huang J; Tao C; Yu Y; Yu F; Zhang H; Gao J; Wang D; Chen Y; Gao J; Zhang G; Zhou G; Liu J; Sun Z; Sun D; Zou H; Xu H; Lu Y; Zhong Y J Biomed Nanotechnol; 2016 Jul; 12(7):1463-77. PubMed ID: 29337484 [TBL] [Abstract][Full Text] [Related]
30. Engineered nanoparticles for drug delivery in cancer therapy. Sun T; Zhang YS; Pang B; Hyun DC; Yang M; Xia Y Angew Chem Int Ed Engl; 2014 Nov; 53(46):12320-64. PubMed ID: 25294565 [TBL] [Abstract][Full Text] [Related]
31. Design of theranostic nanomedicine (II): synthesis and physicochemical properties of a biocompatible polyphosphazene-docetaxel conjugate. Jun YJ; Park JH; Avaji PG; Park KS; Lee KE; Lee HJ; Sohn YS Int J Nanomedicine; 2017; 12():5373-5386. PubMed ID: 28794629 [TBL] [Abstract][Full Text] [Related]
32. Emergence of nanomedicine as cancer targeted magic bullets: recent development and need to address the toxicity apprehension. Rahman M; Ahmad MZ; Kazmi I; Akhter S; Afzal M; Gupta G; Sinha VR Curr Drug Discov Technol; 2012 Dec; 9(4):319-29. PubMed ID: 22725687 [TBL] [Abstract][Full Text] [Related]
33. [Preparation of docetaxel-loaded nanomicelles and their anti-Lewis lung cancer effect in vitro]. Wang YJ; Wang J; Hao DL; Yue QX; Xie R; DE GJ; Yi H; Zang C; Zhao QH; Chen YJ Zhongguo Zhong Yao Za Zhi; 2019 Jun; 44(11):2251-2259. PubMed ID: 31359650 [TBL] [Abstract][Full Text] [Related]
34. Aptamer-guided nanomedicines for anticancer drug delivery. Alshaer W; Hillaireau H; Fattal E Adv Drug Deliv Rev; 2018 Sep; 134():122-137. PubMed ID: 30267743 [TBL] [Abstract][Full Text] [Related]
35. Nanodrugs used in cancer therapy. Kopeckova K; Eckschlager T; Sirc J; Hobzova R; Plch J; Hrabeta J; Michalek J Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2019 Jun; 163(2):122-131. PubMed ID: 30967685 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic Consequences of PLGA Nanoparticles in Docetaxel Drug Delivery. Rafiei P; Haddadi A Pharm Nanotechnol; 2017; 5(1):3-23. PubMed ID: 28948907 [TBL] [Abstract][Full Text] [Related]
37. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma. Varshosaz J; Farzan M World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089 [TBL] [Abstract][Full Text] [Related]
38. Study on intralymphatic-targeted hyaluronic acid-modified nanoliposome: influence of formulation factors on the lymphatic targeting. Tiantian Y; Wenji Z; Mingshuang S; Rui Y; Shuangshuang S; Yuling M; Jianhua Y; Xinggang Y; Shujun W; Weisan P Int J Pharm; 2014 Aug; 471(1-2):245-57. PubMed ID: 24858386 [TBL] [Abstract][Full Text] [Related]
39. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Danhier F; Feron O; Préat V J Control Release; 2010 Dec; 148(2):135-46. PubMed ID: 20797419 [TBL] [Abstract][Full Text] [Related]
40. Targeting Cancer Via Resveratrol-Loaded Nanoparticles Administration: Focusing on In Vivo Evidence. Santos AC; Pereira I; Magalhães M; Pereira-Silva M; Caldas M; Ferreira L; Figueiras A; Ribeiro AJ; Veiga F AAPS J; 2019 Apr; 21(4):57. PubMed ID: 31016543 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]